The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target
was a major breakthrough for the treatment of highly aggressive HER2-positive breast …

Antibody–drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs)
covalently attached to a cytotoxic drug via a chemical linker. It combines both the …

Background An improvement in progression-free survival was shown with trastuzumab
deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast …

As distinct cancer biomarkers have been discovered in recent years, a need to reclassify
tumors by more than their histology has been proposed, and therapies are now tailored to …

DNA materials have emerged as potential nanocarriers for targeted cancer therapy to
precisely deliver cargos with specific purposes. The short half‐life and low bioavailability of …

Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

The large number of emerging antibody-drug conjugates (ADCs) for cancer therapy has
resulted in a significant market 'boom', garnering worldwide attention. Despite ADCs …

Breast cancer (BC) is the most frequent cancer diagnosed in women worldwide. This
heterogeneous disease can be classified into four molecular subtypes (luminal A, luminal B …

Antibody–drug conjugates (ADCs) harness the highly specific targeting capabilities of an
antibody to deliver a cytotoxic payload to specific cell types. They have garnered …

Antibody–drug conjugates (ADC) are one of the fastest growing anticancer drugs. This
approach comprises a mAb conjugated to the cytotoxic payload via a chemical linker that …